{"name":"Xencor, Inc.","slug":"xencor","ticker":"XNCR","exchange":"NASDAQ","domain":"xencor.com","description":"Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager ","hq":"Monrovia, CA","founded":0,"employees":"260","ceo":"Bassil Dahiyat","sector":"Biotech","stockPrice":11.96,"stockChange":-0.42,"stockChangePercent":-3.39,"marketCap":"$887M","metrics":{"revenue":125576000,"revenueGrowth":-86.2,"grossMargin":-152.2,"rdSpend":239434000,"netIncome":-91923000,"cash":444950016,"dividendYield":0,"peRatio":-3.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"XmAb14045 patent cliff ($100M at risk)","drug":"XmAb14045","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Xencor Announces FDA Clearance of Investigational New Drug (IND) Application for XmAb24306","summary":"Xencor announced that the FDA has cleared the IND application for XmAb24306, a monoclonal antibody being developed for the treatment of autoimmune diseases.","drugName":"XmAb24306","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Xencor Reports Third Quarter 2023 Financial Results","summary":"Xencor reported its third quarter 2023 financial results, with revenue of $34.4 million and a net loss of $44.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Xencor Enters into Collaboration Agreement with Novartis","summary":"Xencor announced a collaboration agreement with Novartis to develop and commercialize XmAb20717, a monoclonal antibody being developed for the treatment of cancer.","drugName":"XmAb20717","sentiment":"positive"}],"realNews":[{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNcHJMWkcxakp4RWlyR0hlczhNRzg3RzBGVlRmdFdvd2VZc3NNS0UzNGhJak1iWDV1TTNhekxNWC03VC1QSzVGMm1wZFNScWtVUlJidnUwaUc2dFdXZEptMDZJWWloX3NlTkVEQ3Q0LW9kMGJTdFhsNWtzS2tVTGVaTFJPZkpBUQ?oc=5","date":"2026-03-05","type":"pipeline","source":"Seeking Alpha","summary":"Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ) - Seeking Alpha","headline":"Xencor falls on royalty row with AstraZeneca (XNCR:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxPbDhQSmRyN2xRSHhtU2JvdUp0OVlaeC1JcFFvQ2lvdlNnMTVhaFFIV29teGg0b0o2b1dxVUJ1OE43dFRnZHhYZ0lKN0pDd01KdE42bjhfN2dIOXpHVUVLdkFrdUJfMDl4N3ZIZVQzUGczenR1eWZtckg0WUdKRjh3Y3dGOUZFdndMSkpiaE1tRkFYT0ZkUDZyQVJHNFA3VERGdGZOdWVEdzdpQWZXZFVtbWdfRXRGT2k1U1E?oc=5","date":"2026-03-04","type":"earnings","source":"Business Wire","summary":"Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Business Wire","headline":"Xencor Announces Change to Ultomiris® Royalty Revenue Forecast","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNSDZMZEEtZG5SMXN2bHV1WnlULVdKV3pabTdsSUhXeWo2a2wyMTRFT1M2OFFJQ2RXWHJMRHo5TmZIT1lxakx6d3FMZTVUMXJVNlh0NkdLZFRWZVZFSzM4UmJQWkd6cUs2Z1VOZllKQ19xZFRlWXZ4RnZ0REoza2YwekpIOWdKOV9DZDhic2tCWm85WndSOEdvTllvSlVoY3h5VlEwMy1uak5QVmtLaDNadA?oc=5","date":"2026-02-23","type":"pipeline","source":"Business Wire","summary":"Xencor to Participate at Upcoming Investor Conferences - Business Wire","headline":"Xencor to Participate at Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-13","type":"pipeline","source":"simplywall.st","summary":"Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate - simplywall.st","headline":"Xencor, Inc. (NASDAQ:XNCR) Shares Could Be 28% Below Their Intrinsic Value Estimate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQbHNGdHg5QWNheHRlaXlXNWl4MzE2cndjbnBPSE50RUQ3Z1l6dW9GdnpScHdqRWt6QTZCLUlIUl92OEE5MXd3N0ZlRWdZaUpNOE9QdjVGZzJxNXhGZjc0b1V6VmdhVW8yT0U4cW9WT2o5d2t4RkRsdXdyR0JEVWJjd1dvdUdQT0hJcVhJbVBiMVBteUZhNkFVZnNPWm8yUmk2a2hFeDVLUzZyMzQ5MVBrNE9PLXM2MWZtMUZMaFY1c3lTbEstcjlVckpmcTJidWI3UU5pNTlweUw1TGZ6dFJONU5CQk8tVWhKTDZJUV9CaTdsMS03LWdSLUJiSU94T3piYk9MbmFPNi1YZDg?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"pipeline","source":"simplywall.st","summary":"Is Xencor (XNCR) Now Fairly Priced After Prolonged Share Price Declines - simplywall.st","headline":"Is Xencor (XNCR) Now Fairly Priced After Prolonged Share Price Declines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPYjlqOFBBdng3ZHBIT0JaSnp2bDdfai1PWk9NU0xFWGpqa05qd2pyTVZneENQUXgyeE5TbFhHUUwwUG1lYlBMbWI2a0FVdWNLZXdsNmNPSnI4cDNzUXcxM0otUU9DNzdpTl9vOEtDLUpLWTF6ajh6ajdUbWw5T0M3b3pVbVJKeHJkeDVPWUFHSE5mWUo1aW1IVFBxazgwMTVyeGNwVWdQemE?oc=5","date":"2026-01-01","type":"pipeline","source":"Seeking Alpha","summary":"Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha","headline":"Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5nYkE3bEd1Tm41aXIyYkdkWm15U0d6QUpqVGxtZmRMWTR3YWZsY1E4dWN2TGd5RWlqaXEwenU0SWlhdUJOanpQOWFlSnItQVM3Z3ZyYVk4bmxycC16ZEJyVmZzT2M3X1M1QUhsRGVobFVXeXQ5RXE0WjFxQm9Zdw?oc=5","date":"2025-11-05","type":"earnings","source":"Yahoo Finance","summary":"Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance","headline":"Xencor (XNCR) Reports Q3 Loss, Misses Revenue Estimates","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1ldF8zLVA4clBvRHBNRDhyYXFUbGtpWHg5T3FtSXFRclJqSWhxNUhBemtBTm5aZ0ttbHptcXVBQXFuLVI1N0pwdmVwTlo1VTlaVWQ4?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"XNCR Stock Price, News & Analysis - Stock Titan","headline":"XNCR Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxONG9UeFQ1UFBIRTVOSzBiUC13V2Yyc2hDRDMzcHBqeUdXNjk1dERtZFpYeF9vc0xuTVd6bHJtc2Zrd0VVUG1nU2hjdjZLYlJmOW5rbUVrWUtSb3Zvc3VSOFl4a2NMRXlsc190Vm1HNlhBYV9nNXZMaENUcnlOcm9SbVE1M1h3Q3M?oc=5","date":"2025-04-11","type":"pipeline","source":"Seeking Alpha","summary":"Xencor, Inc.: No Major Near Term Catalysts (NASDAQ:XNCR) - Seeking Alpha","headline":"Xencor, Inc.: No Major Near Term Catalysts (NASDAQ:XNCR)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPWWN3cGtxT01TVXJRUTh3cTk5R0FrY3J1VHEtNzB1dlpEalNvaV9kMEQ4NkxINTYxNDluUTlnSkhEbEFtOWdwaWRsTFMxRDRGcnpKX2dDRDRPY0lKeV9rR1JYaTJ0MWU2dGNCbHE5MTVZU2NhX1N6cEFZVm5uQjhrdFZ4d1FyWjRjRE1YbkNaaTFpRlpWYnpIcXpIMjVJVXlXeVdZaG9GUHR1OTNLWW05bA?oc=5","date":"2024-10-04","type":"pipeline","source":"Business Wire","summary":"Xencor Announces Upcoming Change to Board of Directors - Business Wire","headline":"Xencor Announces Upcoming Change to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTFB2Ykp4Q0ZjZ0plUFVnTkNaRm9RdTdoSEZvZVloSHZZMGUxSUlMdW9vNXc1QVNGSkQ5bWRsTmEwdktUVG1FVGl2YmJFRFNMaGU5Znc?oc=5","date":"2017-05-24","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Xencor, Inc. (XNCR) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Xencor, Inc. (XNCR) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"}],"patents":[{"drugName":"XmAb14045","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":100000000}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Biogen","Amgen"],"therapeuticFocus":["Autoimmune Diseases","Cancer"],"financials":{"source":"sec_edgar+yahoo","revenue":125576000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":125576000,"period":"2025-12-31"},{"value":110493000,"period":"2024-12-31"},{"value":110493000,"period":"2024-12-31"},{"value":168338000,"period":"2023-12-31"},{"value":174615000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":239434000,"rdSpendHistory":[{"period":"2025-12-31","value":239434000},{"period":"2024-12-31","value":227686000},{"period":"2023-12-31","value":253598000},{"period":"2022-12-31","value":199563000}],"sgaSpend":63644000,"operatingIncome":-177502000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-177502000},{"period":"2024-12-31","value":-178408000},{"period":"2023-12-31","value":-132362000},{"period":"2022-12-31","value":-82473000}],"netIncome":-91923000,"netIncomeHistory":[{"period":"2025-12-31","value":-91923000},{"period":"2024-12-31","value":-232618000},{"period":"2023-12-31","value":-133133000},{"period":"2022-12-31","value":-55181000}],"eps":-1.24,"epsHistory":[{"period":"2025-12-31","value":-1.24},{"period":"2024-12-31","value":-3.58},{"period":"2023-12-31","value":-2.08},{"period":"2022-12-31","value":-0.93}],"cash":54073000,"cashHistory":[{"period":"2025-12-31","value":54073000},{"period":"2024-12-31","value":40875000},{"period":"2023-12-31","value":53790000},{"period":"2022-12-31","value":53942000}],"totalAssets":875495000,"totalLiabilities":239908000,"totalDebt":187747000,"equity":635587000,"operatingCashflow":-135117000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-135117000},{"period":"2024-12-31","value":-202188000},{"period":"2023-12-31","value":-77926000},{"period":"2022-12-31","value":24485000}],"capex":-3150000,"capexHistory":[{"period":"2025-12-31","value":-3150000},{"period":"2024-12-31","value":-9512000},{"period":"2023-12-31","value":-21251000},{"period":"2022-12-31","value":-43404000}],"freeCashflow":-138267000,"dividendsPaid":null,"buybacks":null,"employees":260,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":17041000,"ebit":3088000,"ebitda":5665000,"period":"2025-12-31","revenue":28237000,"epsBasic":-0.09,"netIncome":-6653000,"rdExpense":64824000,"epsDiluted":-0.09,"grossProfit":null,"operatingIncome":-53628000},{"sga":14151000,"ebit":1638000,"ebitda":4227000,"period":"2025-09-30","revenue":20999000,"epsBasic":-0.08,"netIncome":-6027000,"rdExpense":54367000,"epsDiluted":-0.08,"grossProfit":null,"operatingIncome":-47519000},{"sga":15115000,"ebit":-22832000,"ebitda":-20179000,"period":"2025-06-30","revenue":43608000,"epsBasic":-0.41,"netIncome":-30825000,"rdExpense":61665000,"epsDiluted":-0.41,"grossProfit":null,"operatingIncome":-33172000},{"sga":17337000,"ebit":-39600000,"ebitda":-36907000,"period":"2025-03-31","revenue":32732000,"epsBasic":-0.66,"netIncome":-48418000,"rdExpense":58578000,"epsDiluted":-0.66,"grossProfit":null,"operatingIncome":-43183000},{"sga":14915000,"ebit":-18699000,"ebitda":-15705000,"period":"2024-12-31","revenue":70018000,"epsBasic":-0.62,"netIncome":-53479000,"rdExpense":51056000,"epsDiluted":-0.62,"grossProfit":null,"operatingIncome":4047000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.96,"previousClose":12.38,"fiftyTwoWeekHigh":18.69,"fiftyTwoWeekLow":6.92,"fiftyTwoWeekRange":"6.92 - 18.69","fiftyDayAverage":12.3,"twoHundredDayAverage":12.39,"beta":0.93,"enterpriseValue":648086976,"forwardPE":-3.4,"priceToBook":1.35,"priceToSales":9.11,"enterpriseToRevenue":6.66,"enterpriseToEbitda":-3.21,"pegRatio":0,"ebitda":-201795008,"ebitdaMargin":-207.3,"freeCashflow":-76885376,"operatingCashflow":-186524992,"totalDebt":175164000,"debtToEquity":34,"currentRatio":6.57,"returnOnAssets":-16.2,"returnOnEquity":-29.8,"analystRating":"1.5 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":12,"targetMeanPrice":28.5,"targetHighPrice":43,"targetLowPrice":14,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.2,"institutionHeldPercent":119.4,"sharesOutstanding":74141596,"floatShares":54656443,"sharesShort":10529038,"shortRatio":13.63,"shortPercentOfFloat":14.2,"epsTrailing":-2.29,"epsForward":-3.56,"revenuePerShare":1.3,"bookValue":8.84,"officers":[{"age":55,"name":"Dr. Bassil I. Dahiyat Ph.D.","title":"Co-Founder, CEO, President & Director"},{"age":47,"name":"Mr. Bart Jan Cornelissen","title":"Senior VP & CFO"},{"age":61,"name":"Dr. John R. Desjarlais Ph.D.","title":"Executive VP of Research & Chief Scientific Officer"},{"age":53,"name":"Ms. Celia E. Eckert J.D.","title":"Senior VP, General Counsel & Corporate Secretary"},{"age":null,"name":"Mr. Charles  Liles","title":"Associate Director and Head of Corporate Communications & Investor Relations"},{"age":null,"name":"Ms. Jennifer  Sandoz","title":"Senior VIce President of Human Resources"},{"age":60,"name":"Mr. Kirk  Rosemark RAC","title":"Senior Vice President of Regulatory Affairs & Quality Assurance"},{"age":null,"name":"Mr. Eric P. Kowack","title":"Senior Vice President of Program Leadership & Alliance Management"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.xencor.com","phone":"626 305 5900"}}